Home Cart Sign in  
Chemical Structure| 1001908-89-9 Chemical Structure| 1001908-89-9

Structure of SRT 2183
CAS No.: 1001908-89-9

Chemical Structure| 1001908-89-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SRT2183 is a small-molecule activator of the sirtuin subtype SIRT1.

Synonyms: SRT 2183

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SRT 2183

CAS No. :1001908-89-9
Formula : C27H24N4O2S
M.W : 468.57
SMILES Code : O=C(NC1=CC=CC=C1C2=CN3C(SC=C3CN4C[C@H](O)CC4)=N2)C5=CC=C6C=CC=CC6=C5
Synonyms :
SRT 2183
MDL No. :MFCD22419825

Safety of SRT 2183

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of SRT 2183

epigenetics

Isoform Comparison

Biological Activity

Description
SRT 2183 is a selective activator of Sirtuin-1 (SIRT1), with an EC1.5 of 0.36 μM[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
HUVEC 10 μM 24, 48, 72 h Evaluate the toxicity of HTCG@TA on normal cells, results showed over 80% cell survival PMC6637499
Mouse renal medullary interstitial cells 5 μM 6 hours SRT2183 dose-dependently increased COX2 expression. PMC2846063
SF767 10 μM 24, 48, 72 h SRT2183 inhibited the growth of SF767 cells. PMC6637499
SF539 10 μM 24, 48, 72 h SRT2183 inhibited the growth of SF539 cells. PMC6637499
LN229 10 μM 24, 48, 72 h HJC0152 inhibited the proliferation of LN229 cells with an IC50 value of 1.749 μM. PMC6637499
MOLT-4 cells 10 μM 48 hours SRT2183 induced apoptosis in MOLT-4 cells with an IC50 of approximately 8.7 μM. PMC3674366
Reh cells 10 μM 48 hours To study resistance to Moxetumomab pasudotox PMC3674366
SK-OV-3 cells 1 μM 14 days PMC7762476
U2OS cells 10 μM Significantly inhibited U2OS cell growth PMC2753457
U87 40 μmol/L 24 hours HJC0152 inhibited the proliferation of U87 cells with an IC50 value of 5.396 μM. PMC10791567
U87 20 μmol/L 1 hour HJC0152 inhibited the proliferation of U87 cells with an IC50 value of 5.396 μM. PMC10791567
Mouse renal medullary interstitial cells 5-20 μM 8 hours SRT2183 dose-dependently increased COX2 expression. PMC2846063
U118 20 μmol/L 1 hour Erianin significantly inhibited the viability of GBM cells, with inhibitory capacity dependent on both time and concentration. PMC10791567
U251 20 μmol/L 1 hour Evaluate the effect of MYCi975 on the viability of U251 cells, results showed that MYCi975 significantly inhibited cell viability PMC10791567
U87MG 10 μM 24, 48, 72 h Evaluate the effect of CBL0137 on FACT, p53, and NF-ĸB. Results showed that CBL0137 caused loss of FACT subunits from the soluble protein fraction, significantly increased p53 expression, and inhibited NF-ĸB-dependent transcription. PMC6637499
Ly3 cells 10 μM 24 hours SRT2183 reduced the acetylation levels of STAT3 and NF-κB in Ly3 cells and inhibited their DNA-binding activity. PMC3674366
Nalm-6 cells 10 μM 48 hours SRT2183 significantly inhibited the proliferation of Nalm-6 cells with an IC50 of approximately 3.2 μM and induced apoptosis. PMC3674366
SW626 cells 1 μM 14 days To evaluate the effect of SRT2183 on cell growth, results showed that SRT2183 inhibited the growth of SW626 cells. PMC7762476
Caov-3 cells 1 μM 14 days To evaluate the effect of SRT2183 on cell growth, results showed that SRT2183 inhibited the growth of Caov-3 cells. PMC7762476
A2780 cells 1 μM 24 and 48 hours To evaluate the effect of SRT2183 on apoptosis, results showed that SRT2183 significantly increased apoptosis in A2780 cells. PMC7762476
OVCAR-3 cells 1 μM 24 and 48 hours To evaluate the effect of SRT2183 on apoptosis, results showed that SRT2183 significantly increased apoptosis in OVCAR-3 cells. PMC7762476
U87 and U251 glioma cells 10 μmol/L 1 h pretreatment followed by co-incubation with 450 nmol/L DPT for 24 h SRT2183 enhanced DPT-induced PARP1 activation and glioma cell death, as evidenced by increased LDH release, upregulation of PARP1 and PAR, and elevated levels of γ-H2AX and phospho-ATM. PMC10545831
Bone marrow-derived macrophages (BMMs) 1 μM 4 days SRT2183 inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. PMC4520518

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.13mL

0.43mL

0.21mL

10.67mL

2.13mL

1.07mL

21.34mL

4.27mL

2.13mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories